GlassScriptPhysician profile
Marta Meyers
NPI 1154328755
$4,776.03
in general payments reported to CMS, 2019-2025
39 companies · $682 in 2025
The $682 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $198 · 2021: $290 · 2022: $1,107 · 2023: $978 · 2024: $827 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.11 | 2021-2025 | |
| Pfizer INC. | $447.15 | 2019-2025 | |
| Lilly USA, LLC | $434.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $390.20 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $375.05 | 2019-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $299.58 | 2022-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $231.36 | 2019-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $198.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $192.17 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.92 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $137.22 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.33 | 2019-2024 | Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $99.10 | 2022 | |
| Almatica Pharma LLC | $88.07 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Kowa Pharmaceuticals America, INC. | $87.63 | 2019-2025 | Zoryve, Livalo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Meyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.